TY - JOUR
T1 - Oncolytic virotherapy for malignant tumor
T2 - Current clinical status
AU - Zhang, Yuhui
AU - Liu, Zhuoming
N1 - Funding Information:
The cost of the manuscript was paid by the grant from the National Natural Science Foundation of China (No. 81201988) and Shanghai Municipal committee of Science and Technology (No. 12140901802).
Publisher Copyright:
© 2019 Bentham Science Publishers.
PY - 2019
Y1 - 2019
N2 - Oncolytic viruses, as novel biological anti-tumor agents, provide anti-tumor therapeutic effects by different mechanisms including directly selective tumor cell lysis and secondary systemic anti-tumor immune responses. Some wide-type and genetically engineered oncolytic viruses have been applied in clinical trials. Among them, T-Vec has a significant therapeutic effect on melanoma patients and received the approval of the US Food and Drug Administration (FDA) as the first oncolytic virus to treat cancer in the US. However, the mechanisms of virus interaction with tumor and immune systems have not been clearly elucidated and there are still no “gold standards” for instructions of virotherapy in clinical trials. This Review collected the recent clinical trials data from 2005 to summarize the basic oncolytic viruses biology, describe the application in recent clinical trials, and discuss the challenges in the application of oncolytic viruses in clinical trials.
AB - Oncolytic viruses, as novel biological anti-tumor agents, provide anti-tumor therapeutic effects by different mechanisms including directly selective tumor cell lysis and secondary systemic anti-tumor immune responses. Some wide-type and genetically engineered oncolytic viruses have been applied in clinical trials. Among them, T-Vec has a significant therapeutic effect on melanoma patients and received the approval of the US Food and Drug Administration (FDA) as the first oncolytic virus to treat cancer in the US. However, the mechanisms of virus interaction with tumor and immune systems have not been clearly elucidated and there are still no “gold standards” for instructions of virotherapy in clinical trials. This Review collected the recent clinical trials data from 2005 to summarize the basic oncolytic viruses biology, describe the application in recent clinical trials, and discuss the challenges in the application of oncolytic viruses in clinical trials.
KW - Cancer
KW - Clinical trial
KW - Genetically engineered
KW - Malignant tumor
KW - Oncolytic viruses
KW - Virotherapy
UR - http://www.scopus.com/inward/record.url?scp=85077487197&partnerID=8YFLogxK
U2 - 10.2174/1381612825666191104090544
DO - 10.2174/1381612825666191104090544
M3 - Review article
C2 - 31682207
AN - SCOPUS:85077487197
SN - 1381-6128
VL - 25
SP - 4251
EP - 4263
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 40
ER -